IGM Biosciences (IGMS) News Today → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free IGMS Stock Alerts $9.20 -0.07 (-0.76%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 10:57 AM | marketbeat.comIGM Biosciences, Inc. (NASDAQ:IGMS) Short Interest UpdateIGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) was the target of a large growth in short interest in April. As of April 30th, there was short interest totalling 6,240,000 shares, a growth of 18.9% from the April 15th total of 5,250,000 shares. Based on an average daily volume of 289,500 shares, the days-to-cover ratio is currently 21.6 days. Approximately 29.9% of the shares of the company are sold short.May 13 at 3:56 AM | americanbankingnews.comIGM Biosciences (NASDAQ:IGMS) Rating Reiterated by WedbushMay 12 at 3:33 AM | seekingalpha.comIGM Biosciences: Unlikely To Move The Needle Again In 2024May 10, 2024 | finance.yahoo.comIGM Biosciences Inc (IGMS) Q1 2024 Earnings: Aligns with EPS Projections Amidst Clinical ...May 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), IGM Biosciences (IGMS) and Elanco Animal Health (ELAN)May 9, 2024 | markets.businessinsider.comWedbush Keeps Their Buy Rating on IGM Biosciences (IGMS)May 9, 2024 | marketbeat.comWedbush Reiterates "Outperform" Rating for IGM Biosciences (NASDAQ:IGMS)Wedbush restated an "outperform" rating and issued a $20.00 price objective on shares of IGM Biosciences in a research note on Thursday.May 9, 2024 | investorplace.comIGMS Stock Earnings: IGM Biosciences Meets EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comIGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | globenewswire.comIGM Biosciences to Present at the 2024 RBCCM Global Healthcare ConferenceMay 6, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Shares Gap Down to $10.07IGM Biosciences (NASDAQ:IGMS) Shares Gap Down to $10.07May 4, 2024 | americanbankingnews.comIGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 2, 2024 | markets.businessinsider.comIGM Biosciences Upgraded to Buy: What Does It Mean for the Stock?April 26, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Trading Up 13.7%IGM Biosciences (NASDAQ:IGMS) Shares Up 13.7%April 19, 2024 | finance.yahoo.comIGM Biosciences Insiders Placed Bullish Bets Worth US$992.2kApril 18, 2024 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About IGM BiosciencesApril 18, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)April 18, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Receives "Neutral" Rating from HC WainwrightHC Wainwright reiterated a "neutral" rating and issued a $12.00 price objective on shares of IGM Biosciences in a research note on Thursday.April 17, 2024 | bizjournals.comBig drugmaker's cancer rollback trickles down to another Bay Area companyApril 17, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Shares Down 4.9% IGM Biosciences (NASDAQ:IGMS) Shares Down 4.9%April 17, 2024 | finanznachrichten.deIGM Biosciences, Inc.: IGM Biosciences Announces Refocusing of Sanofi CollaborationApril 17, 2024 | markets.businessinsider.comWhy IGM Biosciences Is Rising In Pre-market?April 17, 2024 | finance.yahoo.comIGM Biosciences Announces Refocusing of Sanofi CollaborationApril 17, 2024 | globenewswire.comIGM Biosciences Announces Refocusing of Sanofi CollaborationApril 15, 2024 | marketbeat.comIGM Biosciences, Inc. (NASDAQ:IGMS) Short Interest Up 9.7% in MarchIGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 5,220,000 shares, a growth of 9.7% from the March 15th total of 4,760,000 shares. Currently, 25.1% of the company's shares are short sold. Based on an average daily volume of 281,700 shares, the short-interest ratio is currently 18.5 days.April 10, 2024 | globenewswire.comIGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology ForumApril 9, 2024 | marketbeat.comIGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of IGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and four have given a bApril 8, 2024 | finance.yahoo.comIGM Biosciences, Inc. (IGMS)April 5, 2024 | marketbeat.comIGM Biosciences, Inc. (NASDAQ:IGMS) Short Interest Up 5.5% in MarchIGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 4,760,000 shares, an increase of 5.5% from the February 29th total of 4,510,000 shares. Based on an average daily trading volume, of 291,100 shares, the days-to-cover ratio is presently 16.4 days. Approximately 22.9% of the company's shares are short sold.April 3, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Trading Down 3.2%IGM Biosciences (NASDAQ:IGMS) Shares Down 3.2%April 1, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Shares Gap Up to $9.65IGM Biosciences (NASDAQ:IGMS) Shares Gap Up to $9.65March 29, 2024 | insidertrades.comIGM Biosciences, Inc. (NASDAQ:IGMS) Director Acquires $937,690.26 in StockMarch 28, 2024 | marketbeat.comIGM Biosciences, Inc. (NASDAQ:IGMS) Director Bros. Advisors Lp Baker Buys 97,473 SharesIGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) Director Bros. Advisors Lp Baker acquired 97,473 shares of the business's stock in a transaction that occurred on Thursday, March 28th. The shares were bought at an average price of $9.62 per share, with a total value of $937,690.26. Following the completion of the transaction, the director now directly owns 3,753,480 shares in the company, valued at $36,108,477.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.March 25, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Trading Down 6.7%IGM Biosciences (NASDAQ:IGMS) Shares Down 6.7%March 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Alpine Immune Sciences (ALPN) and IGM Biosciences (IGMS)March 17, 2024 | insidertrades.comMisbah Tahir Sells 2,897 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) StockMarch 17, 2024 | marketbeat.comHudson Bay Capital Management LP Purchases New Position in IGM Biosciences, Inc. (NASDAQ:IGMS)Hudson Bay Capital Management LP purchased a new stake in shares of IGM Biosciences, Inc. (NASDAQ:IGMS - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 124,260 shares of the companyMarch 15, 2024 | marketbeat.comInsider Selling: IGM Biosciences, Inc. (NASDAQ:IGMS) CFO Sells 2,897 Shares of StockIGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) CFO Misbah Tahir sold 2,897 shares of the company's stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $9.88, for a total value of $28,622.36. Following the completion of the transaction, the chief financial officer now directly owns 92,961 shares in the company, valued at approximately $918,454.68. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.March 15, 2024 | finance.yahoo.comIGMS Apr 2024 22.500 callMarch 15, 2024 | marketbeat.comIGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Rating of "Hold" from BrokeragesShares of IGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) have been assigned a consensus recommendation of "Hold" from the nine analysts that are covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating toMarch 14, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Shares Up 2.7%IGM Biosciences (NASDAQ:IGMS) Trading Up 2.7%March 14, 2024 | marketbeat.comQ1 2024 EPS Estimates for IGM Biosciences, Inc. Increased by Analyst (NASDAQ:IGMS)IGM Biosciences, Inc. (NASDAQ:IGMS - Free Report) - Investment analysts at HC Wainwright boosted their Q1 2024 EPS estimates for shares of IGM Biosciences in a research note issued on Tuesday, March 12th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.81) per share forMarch 11, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Stock Price Down 5.5%IGM Biosciences (NASDAQ:IGMS) Shares Down 5.5%March 9, 2024 | finance.yahoo.comIGM Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 9, 2024 | finanznachrichten.deIGM Biosciences, Inc.: IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 8, 2024 | investorplace.comIGMS Stock Earnings: IGM Biosciences Beats EPS, Misses Revenue for Q4 2023March 7, 2024 | stockhouse.comIGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 7, 2024 | msn.comIGM Biosciences GAAP EPS of -$1.01 beats by $0.08, revenue of $0.7M misses by $0.07MMarch 7, 2024 | globenewswire.comIGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 24, 2024 | msn.comIGM Biosciences (IGMS) Price Target Increased by 9.28% to 21.01 Get IGM Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Did Intel Just Dethrone Nvidia? (Ad)Intel (INTC) just announced a brand-new AI venture - the Aurora supercomputer. This computer was specifically designed for artificial intelligence and is now the fastest AI-centered computer on the planet. You can get all the details here. IGMS Media Mentions By Week IGMS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IGMS News Sentiment▼0.360.57▲Average Medical News Sentiment IGMS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IGMS Articles This Week▼132▲IGMS Articles Average Week Get IGM Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AVBP News AVTE News PHAT News CDMO News CALT News APLT News ATXS News STOK News GHRS News OLMA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IGMS) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeAmerica’s worst nightmare?Porter & CompanyInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxCrypto Millionaire Says: “Buy This $11 AI Coin.”InvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
